Ocular Therapeutix develops sustained-release ophthalmic therapies using its ELUTYX bioresorbable hydrogel platform. Its commercial product DEXTENZA is a dexamethasone intracanalicular insert for post-surgical ocular inflammation and pain and for allergic conjunctivitis itching. The pipeline targets retinal diseases with the goal of reducing treatment burden compared with frequent eye injections or complex drop regimens.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 13.5 | — | -67.8 | — |
| Q3 2025 | 14.5 | — | -69.4 | — |
| Q4 2025 | 13.3 | — | -64.7 | — |
| Q1 2026 | 10.8 | — | -88.6 | — |
| Q2 2026 | 13.5 | 0.1% | -78.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: NeoGenomics, Inc. (NEO), Flywire Corporation (FLYW), Vertex, Inc. (VERX), ePlus inc. (PLUS), Harmony Biosciences Holdings, Inc. (HRMY), PicS N.V. (PICS)